Short-term (5 days) administration of L-thyroxine (0.1 mg/kg i.p. daily) to adult SpragueDawley rats induces a modest degree of cardiac hypertrophy (22% increase in heart weight/body weight ratios) and directionally opposite changes in cardiac adrenoceptors (24% increase in fi-adrenoceptors and 201% decline in ae-adrenoceptors). Pretreatment to influence two events: 1) the transduction of signals to the nucleus that initiate cardiac hypertrophy or /3-receptor synthesis and 2) the insertion of newly synthesized /3-receptors from the Golgi apparatus (where they are first glycosylated) to the plasma membrane. These alternatives were examined during short-term thyroxine administration to adult, euthyroid Sprague-Dawley rats.
Results
In agreement with previous studies,1-3 short-term administration of thyroxine results in cardiac hypertrophy, as evidenced by increased heart weight/body weight ratios and higher ventricular weights (Table  1) . Rats treated with colchicine alone had somewhat smaller body weights but normal heart weight/body weight ratios. In the presence of colchicine, thyroxine was still able to induce significant cardiac hypertrophy as well as a small decrease in body weight.
The influence of hyperthyroidism on the cardiac 13-adrenoceptors is shown in Figure 1 . As expected, there was a significant (24%) increase in membranebound 18-adrenoceptors in hyperthyroid compared with euthyroid rats. In colchicine-treated rats, however, thyroxine was considerably less effective, resulting in only 10% increase in 13-receptor numbers. The affinity of the 13- (Figure 2 ), so that the number of vesicular 13-receptors as a proportion of the total was unchanged. In the colchicine group, however, the proportion of vesicular 13-receptors was higher both with and without concomitant thyroxine administration. This difference reached statistical significance only after 2 weeks of colchicine, when a substantial decline in the density of membrane-bound ,3-receptors is almost exactly counterbalanced by an increase in the vesicular receptors. In contrast to the ,B-adrenoceptors, the number of the a1-adrenoceptors declined after thyroxine administration to 80% of the controls (Table 2 ). In colchicinetreated rats, however, this decline in a-adrenoceptor numbers was totally prevented. As shown in Table 3 , the total number of 13-adrenoceptors was significantly increased by thyroxine, and this increase was attenuated by colchicine. Reciprocal changes were induced in cardiac a1-adrenoceptors. After 2 weeks of colchicine, there were only minor (about 10%) changes in the total number of cardiac adrenoceptors, in contrast to the evidence for redistribution (Figure 2 ). Discussion Although significant progress has been made in the last few years in elucidating the biochemical and structural consequences of cardiac hypertrophy, the early events in its induction remain elusive and may differ depending on the initiating stimulus. The ef- fects of thyroxine on the heart are thought to result from its interaction with nuclear receptors and consequent modification of specific gene transcription.9
The sequence and regulation of the steps leading to the nuclear localization of thyroxine and its interaction with gene control elements are not well understood. It is possible that microtubules are involved in the transduction of signals to the nucleus, which result in either repression or enhancement of specific gene transcription.10-12 Examples of repression are provided by the a1-adrenoceptor, 83-myosin, and thyrotropin genes, whereas enhanced transcription is thought to explain the effects on ,B-adrenoceptors and a-myosin gene expression.
The most striking aspect of the present study is the observed dissociation induced by colchicine between the effects of thyroxine on cardiac hypertrophy and on the adrenoceptor numbers. Since the percent increase in ventricular weight and heart weight/body weight ratios in response to thyroxine was unaltered by colchicine, a generalized inhibition of protein synthesis is unlikely. This contrasts with the profound inhibition of the thyroxine effects on the cardiac ,Band a1-adrenoceptors despite their opposite direction. Since both membrane and vesicular fractions were affected by colchicine, the predominant effect appears to be through inhibition of 13-receptor synthesis. We noted, however, that the percentage of ,3-receptors recovered in the vesicular fraction was somewhat higher in the colchicine-treated rats (group II), suggesting that inhibition of intracellular receptor traffic-in particular, impaired insertion of newly synthesized receptors into the plasma membrane -may also play a role. This is substantiated by the striking redistribution of the ,B-adrenoceptors after 2 weeks of colchicine administration (Figure 2 ), which suggests an intracellular receptor "traffic jam" due to, perhaps, reduced membrane incorporation. The reason that redistribution of 1-adrenoceptors is more striking after 2 weeks of colchicine administration may be because, at earlier stages, the inhibitory effect of colchicine on 13-receptor synthesis induced by thyroxine predominates and prevents a significant intracellular accumulation of 13-receptors. This issue remains to be clarified in future experiments measuring directly the rate of 13-receptor gene transcription in control and colchicine-treated rats. A similar redistribution also appears to be responsible for the apparent decline in the density of membrane-bound a,-adrenoceptors (Table 2) in rats treated with colchicine for 2 weeks (results not shown). This is supported by the fact that the total adrenoceptor numbers were not significantly altered (Table 3) .
The mechanism of the inverse regulation of 13-and a-adrenoceptors by thyroid hormones remains controversial. Reciprocal changes are found using either membranes1-3 or isolated cardiac myocytes'3 and are most probably determined at the level of transcription of the responsible receptor genes. The functional interconversion of a-and 13-receptor responses described in several tissues in response to thyroid hormones appears to be regulated at a postreceptor step (for a review, see Kunos and Ishacl4) .
It is interesting that the pattern of adrenoceptor redistribution after colchicine (i.e., reciprocal changes in 13-and a,-adrenoceptor density and the disproportionate increase in the vesicular receptor pool) resembles that seen in the hypertrophied myocardium of spontaneously hypertensive rats.6 It is possible, therefore, that microtubule dysfunction may, in part, determine the 13-adrenoceptor abnormalities in this and, perhaps, other models of cardiac hypertrophy.
Microtubule dysfunction has been shown to interfere with hormone action at several levels (for a review, see Halll5). Little information exists, however, on the potential role of microtubules on specific gene expression. For example, it has been recently shown that the expression of the casein gene by prolactin'6 or a,-glycoprotein mRNA by the hepatocyte-stimulating factor17 are prevented by microtubule inhibitors, whereas the expression of a heat-shock protein in the mammalian nervous system is strongly influenced by agents affecting microtubule stability.18 A perinuclear microtubule system has been demonstrated in the cardiac myocyte and undergoes striking proliferation and rearrangement during the induction of cardiac hypertrophy.19 However, no data are yet available on the possible involvement of microtubules in cardiac gene expression. In addition, it should be stressed that we have, as yet, no direct evidence that transcription of adrenoceptor genes is altered by either thyroxine or colchicine (although this remains the primary working hypothesis). An alternative explanation would be a colchicine effect on a posttranscriptional step, for example, on the stability of mRNA.20 At least in the case of the a,-glycoprotein mRNA,17 however. the inhibitory effect seems to be exerted at the transcriptional level. Further experiments are needed to clarify this issue.
